Pancreatitis Initiated Pancreatic Ductal Adenocarcinoma: Pathophysiology Explaining Clinical Evidence

Xufeng Tao,Hong Xiang,Yue Pan,Dong Shang,Junchao Guo,Ge Gao,Gary Guishan Xiao
DOI: https://doi.org/10.1016/j.phrs.2021.105595
IF: 10.334
2021-01-01
Pharmacological Research
Abstract:Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant lethal disease due to its asymptomatic at its early lesion of the disease and drug resistance. Target therapy associated with molecular pathways so far seems not to produce reasonable outcomes. Understanding of the molecular mechanisms underlying inflammation-initiated tumorigenesis may be helpful for development of an effective therapy of the disease. A line of studies showed that pancreatic tumorigenesis was resulted from pancreatitis, which was caused synergistically by various pancreatic cells. This review focuses on those players and their possible clinic implications, such as exocrine acinar cells, ductal cells, and various stromal cells, including pancreatic stellate cells (PSCs), macrophages, lymphocytes, neutrophils, mast cells, adipocytes and endothelial cells, working together with each other in an inflammation-mediated microenvironment governed by a myriad of cellular signaling networks towards PDAC.
What problem does this paper attempt to address?